Business
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
Phase 2 open-label study data reinforce donidalorsen's potential to be a best-in-class prophylactic treatment for patients living with hereditary
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"Phase 2 open-label study data reinforce donidalorsen's potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedemaIonis is preparing to launch donidalorsen, one of its three near-term commercial opportunitiesCARLSBAD, Calif., Feb. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive interim data from a Phase 2 open-label extension (OLE) study of donidalorsen, an investigational antisense medicine for the treatment of patients with hereditary angioedema (HAE). Positive interim data presented in November 2022 showed that treatment with donidalorsen resulted in an overall sustained mean reduction in HAE attack rates of 95% from baseline. In the latest update, patients treated for one year with donidalorsen showed a clinically meaningful 24-point mean improvement in their Angioedema Quality of Life (AE-QoL) total score relative to baseline with improvements observed in all domains. An improvement of 6 points or more is considered clinically meaningful1.\n\n \n \n \n \n \n \n\n \nThese long-term, open-label data will be presented at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas, February 24-27. Additional details can be found on the AAAAI website.\n\"The improvement in quality of life demonstrated in patients treated with donidalorsen for one year were clinically meaningful and further support our belief in this medicine's potential to be a best-in-class prophylactic treatment for patients with HAE,\" said Richard S. Geary, Ph.D., executive vice president and chief development officer at Ionis. \"We continue to be pleased with the progress of the Phase 3 OASIS study of donidalorsen, which remains on track to complete enrollment this year.\"\nPoster titles:\nPoster #399: Phase 2 Open-Label Extension Study with Donidalorsen in Patients with Hereditary Angioedema: Updated Interim Analysis with Quality-of-Life DataPoster #400: Phase 2 Open-Label Extension Study with Donidalorsen Treatment in Patients with Hereditary Angioedema: Pharmacodynamic DataPoster #412: The Impact of Donidalorsen Taken Every 8 Weeks in Patients with Hereditary AngioedemaAbout the Phase 2 OLE Study\nPatients who completed the blinded, placebo-controlled Phase 2 study were eligible for enrollment in the OLE study. There were...